The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial
There is a high need for novel treatment options in relapsed and refractory diffuse large B-cell lymphoma. Single agent mammalian target of rapamycin (mTOR) inhibitor treatment has shown promising efficacy in this entity. Here, we report on the results of the mTOR-inhibitor temsirolimus combined to...
Main Authors: | Mathias Witzens-Harig, Andreas Viardot, Ulrich Keller, Julia Wosniok, Oliver Deuster, Jennifer Klemmer, Anne-Marie Geueke, Julia Meißner, Anthony D. Ho, Johannes Atta, Reinhard Marks, Paul La Rosée, Christian Buske, Martin H. Dreyling, Georg Hess |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2021-10-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000636 |
Similar Items
-
Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
by: Georg Hess, et al.
Published: (2020-06-01) -
Chemo-enzymatische asymmetrische Synthesen mit DHAP-Aldolasen
by: Phung, Nga
Published: (2004) -
Physiological effects of autotoxicity due to DHAP stress on Picea schrenkiana regeneration.
by: Li Yang, et al.
Published: (2017-01-01) -
Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients
by: Hu GF, et al.
Published: (2016-07-01) -
Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial
by: Unterhalt Michael, et al.
Published: (2011-02-01)